Asymmetric Dimethylarginine Predicts One-year Recurrent Cardiovascular Events: Potential Biomarker of "Toxin Syndrome" in Coronary Heart Disease

Overview

Journal Chin J Integr Med

Date 2019 May 9

PMID 31065970

Citations 2

Authors

Hao Xu

Zhuo Chen

Qing-Hua Shang

Zhu-Ye Gao

Chang-An Yu

Da-Zhuo Shi

Ke-Ji Chen

Affiliations

Soon will be listed here.

Abstract

Objective: To examine the prognostic value of serum levels of asymmetric dimethylarginine (ADMA) in patients with stable coronary heart disease (CHD) thus explore a potential biomarker of "toxin syndrome" in CHD.

Methods: In this prospective nested case-control study, 36 of 1,503 Chinese patients with stable CHD experienced at least 1 recurrent cardiovascular event (RCE) during 1-year follow-up. Serum levels of ADMA at the start of follow-up were compared between these 36 cases and 36 controls which matched to cases in terms of gender, age, history of hypertension, and myocardial infarction.

Results: Based on the crude model, subjects in the 2 highest ADMA quartiles showed significantly higher risk of developing RCE than those in the lowest ADMA quartile [odds ratio (OR) 4.09, 95% confidence interval (CI) 1.01 to 16.58; OR 6.76, 95% CI 1.57 to 29.07]. This association was also observed in the case-mix model (OR 5.51, 95% CI 1.23 to 24.61; OR 7.83, 95% CI 1.68 to 36.41) and multivariable model (OR 6.64, 95% CI 1.40 to 31.49: OR 13.14, 95% CI 2.28 to 75.71) after adjusting for confounders. The multivariable model which combined ADMA and high-sensitivity C-reactive protein (hsCRP) showed better predictive power with areas under the receiver operator characteristic curves (0.779) than the model of either ADMA (0.694) or hsCRP (0.636).

Conclusion: Serum ADMA level may be a potential biomarker of "toxin syndrome" in CHD which shows favorable prognostic value in predicting 1-year RCE in patients with stable CHD. [The registration number is ChiCTR-PRNRC-07000012].

Citing Articles

Investigation into the Potential Mechanism of Radix Paeoniae Rubra Against Ischemic Stroke Based on Network Pharmacology.

Wen T, Xin G, Zhou Q, Wang T, Yu X, Li Y Nutrients. 2025; 16(24.

PMID: 39771032 PMC: 11678013. DOI: 10.3390/nu16244409.

Oxidative Stress Parameters as Biomarkers of Cardiovascular Disease towards the Development and Progression.

Kong A, Lai K, Hee C, Loh J, Lim S, Sathiya M Antioxidants (Basel). 2022; 11(6).

PMID: 35740071 PMC: 9219727. DOI: 10.3390/antiox11061175.

Elucidation of the Mechanisms and Effective Substances of Paeoniae Radix Rubra Against Toxic Heat and Blood Stasis Syndrome With a Stage-Oriented Strategy.

Xu J, Xu F, Wang W, Zhang Y, Hao B, Shang M Front Pharmacol. 2022; 13:842839.

PMID: 35308239 PMC: 8931751. DOI: 10.3389/fphar.2022.842839.

References

Valkonen V, Paiva H, Salonen J, Lakka T, Lehtimaki T, Laakso J . Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2002; 358(9299):2127-8. DOI: 10.1016/S0140-6736(01)07184-7. View

Xiong Y, Fu Y, Fu S, Zhou H . Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes. J Cardiovasc Pharmacol. 2003; 42(2):191-6. DOI: 10.1097/00005344-200308000-00006. View

Lu T, Ding Y, Charng M, Lin S . Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol. 2003; 26(10):458-64. PMC: 6654648. DOI: 10.1002/clc.4960261006. View

Krempl T, Maas R, Sydow K, Meinertz T, Boger R, Kahler J . Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J. 2005; 26(18):1846-51. DOI: 10.1093/eurheartj/ehi287. View

Schnabel R, Blankenberg S, Lubos E, Lackner K, Rupprecht H, Espinola-Klein C . Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005; 97(5):e53-9. DOI: 10.1161/01.RES.0000181286.44222.61. View

Kielstein J, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J . ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke. 2006; 37(8):2024-9. DOI: 10.1161/01.STR.0000231640.32543.11. View

Jiang J, Zhang X, Li N, Rang W, Feng-Ye , Hu C . Probucol decreases asymmetrical dimethylarginine level by alternation of protein arginine methyltransferase I and dimethylarginine dimethylaminohydrolase activity. Cardiovasc Drugs Ther. 2006; 20(4):281-94. DOI: 10.1007/s10557-006-9065-1. View

Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel K, Goudeva L . Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J. 2006; 152(3):493.e1-8. DOI: 10.1016/j.ahj.2006.06.005. View

Mittermayer F, Krzyzanowska K, Exner M, Mlekusch W, Amighi J, Sabeti S . Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol. 2006; 26(11):2536-40. DOI: 10.1161/01.ATV.0000242801.38419.48. View

10.

Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm B, Winkelmann B . Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem. 2006; 53(2):273-83. DOI: 10.1373/clinchem.2006.076711. View

11.

Siroka R, Trefil L, Rajdl D, Racek J, Cibulka R . Asymmetric dimethylarginine--comparison of HPLC and ELISA methods. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 850(1-2):586-7. DOI: 10.1016/j.jchromb.2006.12.009. View

12.

Garcia R, Perez M, Maas R, Schwedhelm E, Boger R, Lopez-Jaramillo P . Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol. 2007; 122(2):176-8. DOI: 10.1016/j.ijcard.2006.11.058. View

13.

Maas R, Schulze F, Baumert J, Lowel H, Hamraz K, Schwedhelm E . Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in.... Clin Chem. 2007; 53(4):693-701. DOI: 10.1373/clinchem.2006.081893. View

14.

Szuba A, Podgorski M . Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective clinical trials. Pharmacol Rep. 2007; 58 Suppl:16-20. View

15.

Stuhlinger M, Conci E, Haubner B, Stocker E, Schwaighofer J, Cooke J . Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury. Cardiovasc Res. 2007; 75(2):417-25. DOI: 10.1016/j.cardiores.2007.04.030. View

16.

Munteanu A, Zingg J . Cellular, molecular and clinical aspects of vitamin E on atherosclerosis prevention. Mol Aspects Med. 2007; 28(5-6):538-90. DOI: 10.1016/j.mam.2007.07.001. View

17.

Nicholls S, Wang Z, Koeth R, Levison B, Delfraino B, Dzavik V . Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction. Circulation. 2007; 116(20):2315-24. DOI: 10.1161/CIRCULATIONAHA.107.693986. View

18.

Zeller M, Korandji C, Guilland J, Sicard P, Vergely C, Lorgis L . Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2008; 28(5):954-60. DOI: 10.1161/ATVBAHA.108.162768. View

19.

Bermudez V, Bermudez F, Acosta G, Acosta A, Anez J, Andara C . Molecular mechanisms of endothelial dysfunction: from nitric oxide synthesis to ADMA inhibition. Am J Ther. 2008; 15(4):326-33. DOI: 10.1097/MJT.0b013e318160beda. View

20.

Gutierrez O, Mannstadt M, Isakova T, Rauh-Hain J, Tamez H, Shah A . Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359(6):584-92. PMC: 2890264. DOI: 10.1056/NEJMoa0706130. View